期刊文献+

10-HCPT对人肝癌细胞QGY和HepG2生长增殖的抑制作用

Inhibition on growth and proliferation of human hepatoma cell lines QGY and HepG2 treated by 10-HCPT
在线阅读 下载PDF
导出
摘要 目的 :探讨 10 -HCPT对人肝癌细胞QGY和HepG2生长增殖的影响。 方法 :分别用不同浓度 10 -HCPT作用QGY和HepG2细胞 4 8h和相同浓度作用不同时间 ,以MTT法检测细胞生长指数 (GI) ,软琼脂克隆形成试验检测细胞克隆形成率。结果 :10~ 36 0 μg/ml和 30~ 36 0 μg/ml 10 -HCPT分别作用QGY和HepG2细胞 4 8h后 ,均有显著性生长抑制作用 (P<0 .0 5 ) ,且呈量效依赖关系。 10 0 μg/ml10 -HCPT作用 2 4h、36、4 8和 72h对两种细胞均具有显著性抑制作用 (P <0 .0 5 )。实验组两种细胞克隆形成率较对照组均显著降低 (P <0 .0 5 )。结论 :10 Objective:To investigate the effects of 10-HCPT on the growth and proliferation of human hepatoma cell lines QGY and HepG2 in vitro.Methods:QGY and HepG2 were cultured in RPMI1640.They were treated by different concentrations of 10-HCPT for 48 hours,and by a dose of 100μg/ml of 10-HCPT for different hours.The cell growth indexes (GI) were detected by MTT colorimetric assay.The clone formation rates of QGY and HepG2 were observed by soft agar assay.Results:The GI of HepG2 and QGY cells treated by 10-HCPT with concentration 10~360μg μg/ml and 30~360μg μg/ml were significantly lower than that of control groups respectively ( P <0.05),and the inhibitive effect increased with concentrations ranging from 30 to 360μg/ml in a dose-dependent manner.The effects of 100μg/ml10-HCPT on the growth of QGY and HepG2 cells for 24 hours were significant as compared with control groups( P< 0.05).The inhibition in 36~72 hours was highly significant ( P <0.01),while not significant among themselves ( P >0.05).The clone formation rates of QGY and HepG2 of experimental groups were significantly lower than that of control groups respectively ( P <0.01).Conclution:10-HCPT could inhibit the growth and proliferation of human hepatoma cell lines QGY and HepG2 effectively in vitro.
出处 《重庆医科大学学报》 CAS CSCD 2004年第3期305-307,共3页 Journal of Chongqing Medical University
关键词 10-羟基喜树碱 肝癌:HepG2 QGY 10-HCPT Hepatoma HepG2 QGY
  • 相关文献

参考文献9

  • 1刘连新,姜洪池,朱安龙,王秀琴,周津,吴旻.DNA依赖蛋白激酶和DNA拓扑异构酶在肝癌组织中的表达[J].中华消化杂志,2001,21(6):331-334. 被引量:7
  • 2姜圣亮,谭江平,石林祥,郝杰民,赵崇德,叶世会.MTT法检测肝癌细胞化疗敏感性方法学探讨[J].同济大学学报(医学版),2002,23(4):296-298. 被引量:11
  • 3Ling Y H,Xu B.Inhibition of phosphoryalation of histone H1 and H2 induced by 10-hydroxycamptothecin,DNA topoisomerase I inhibitor,in murine ascites hepatoma cells [ J ].Acta Pharmacologyica Sinica 1993; 14(6) :546-550.
  • 4Zhang X W,Xu B.Differential regulation of P53,c-Myc,Bcl-2 ,Bax and AFP protein expression,and caspase activity during 10-hydroxycamptothecin-induced apoptosis in HepG2 cells[ J ].Anti-cancer Drugs,2000; 11 (9):747-756.
  • 5Ling Y H,Soler R P,Tseng M T,et al.Effect of DNA topoisomerase Ⅰ inhibitor,10-hydroxycarnptothecin,on the structure and function of nuclei and nuclear matrix in bladder carcinoma MBT-2 cells[ J ].Anticancer Res,1993; 13:1613 -1618.
  • 6Sinha B K.Topoisomcrasc inhibitors,A review of their therapeutic potential in cancer[ J ].Drags,1995; 49:11-19.
  • 7Malonne H,Atassi G DNA topoisomerases targeting drags:mechanisms of action and perspectives [ J ].Anticancer Drugs,1997;8(9) :811-822.
  • 8杨甲梅.合理选择原发性肝癌的治疗方法[J].肝胆外科杂志,2002,10(5):321-322. 被引量:4
  • 9孟繁浩,巩丽颖,佟馨.抗癌药物——喜树碱类衍生物研究进展[J].生命的化学,2002,22(3):265-267. 被引量:17

二级参考文献8

  • 1鄂征.组织培养技术(第2版)[M].北京:人民卫生出版社,1993.12.
  • 2Shen H,Biochim Biophys Acta,1998年,138卷,131页
  • 3Jin S,Cancer Surv,1997年,29卷,221页
  • 4Tazi J,J Mol Med,1997年,75卷,786页
  • 5Teraoka H,FEBS Lett,1996年,393卷,1页
  • 6De Risi J,Nat Genet,1996年,14卷,457页
  • 7Schena M,Science,1995年,270卷,467页
  • 8周成英.羟基喜树碱双途径联合化疗治疗中晚期胃肠癌[J].中国肿瘤临床与康复,1999,6(4):91-92. 被引量:3

共引文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部